ContraFect announces presentation of data at ASM Microbe 2023

ContraFect Corporation announces the presentation of data showing significant activity of its direct lytic agents against the most drug-resistant Gram-negative pathogens, including Pseudomonas aeruginosa, Klebsiella pneumoniae and Burkholderia spp, at ASM Microbe 2023 held from June 15-19, 2023 in Houston, Texas. “The data presented at ASM Microbe is quite powerful. Our ability to demonstrate the potent efficacy of CF-370 in animals infected with lethal strains of Pseudomonas, Klebsiella and Acinetobacter holds great promise for the clinical utility of CF-370 in patients with either hospital-acquired or ventilator-associated pneumonia, including patients with compromised immune systems from cancer, age, or other comorbidities,” said Roger Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect. “Along with the new data showing our ability to engineer agents with potent activity against extremely difficult to treat species of Burkholderia and Yersinia, I believe the ContraFect platform represents one of the last remaining paths towards conquering antimicrobial resistance for the foreseeable future.”